RSV shot uptake under the microscope: how many german babies get protected?
NCT ID NCT06824207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks how many infants in Germany receive nirsevimab, a long-acting antibody that helps protect against severe RSV disease. Researchers will survey parents of babies born during three RSV seasons (2024–2027) to measure immunization rates. The goal is to see how well the new universal recommendation is being followed and to guide future vaccination strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nirsevimab
- What this could lead to
- If successful, this study could help public health officials understand how well RSV immunization is reaching infants, potentially improving future vaccination programs.
- What could go wrong
- This is an observational study that only measures immunization rates, not health outcomes. It cannot prove whether nirsevimab prevents severe RSV disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Germany, Germany, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older adults from RSV?
- One shot, two viruses: could a combined vaccine shield seniors from RSV and HMPV?
- Double defense: new mRNA vaccine targets two lung viruses in seniors
- New RSV shots slash baby hospitalizations? study digs into Real-World data
- New mRNA vaccine candidates for RSV enter human testing